Immune system in the context of HIV-1 infection treated with HAART (HIV-1/HAART Immune System)

The immune system in the context of HIV-1 infection treated with Highly Active Antiretroviral Therapy (HAART) represents a complex biological state characterized by pharmacological viral suppression and partial immunological restoration. HIV-1 primarily targets and destroys CD4+ T lymphocytes, leading to the collapse of adaptive immunity and the onset of AIDS (National Institutes of Health [NIH], 2023). HAART interventions utilize a combination of antiretroviral agents to block viral replication, which typically results in an increase in CD4+ T-cell counts and a significant reduction in the risk of opportunistic infections. However, this state is not a complete return to health; a latent viral reservoir persists in resting memory T cells, and many patients experience chronic, low-grade systemic inflammation that contributes to non-AIDS-defining morbidities such as cardiovascular disease (PubMed, PMC7359333). Furthermore, the rapid recovery of the immune system can sometimes trigger Immune Reconstitution Inflammatory Syndrome (IRIS), an exaggerated inflammatory response to pre-existing subclinical infections (StatPearls, 2023). Understanding this system is vital for developing curative strategies and managing the long-term health of individuals living with HIV.

Other names

HIV-1 infected immune systemART-treated HIV infectionImmune reconstitution in HIVHAART-suppressed HIV infection

Highly Active Antiretroviral Therapy (HAART) works by combining multiple antiretroviral drugs that target different stages of the HIV-1 life cycle, including reverse transcription (NRTIs/NNRTIs), integration (INSTIs), and polyprotein cleavage (Protease Inhibitors), thereby suppressing viral load to undetectable levels and allowing for the quantitative and qualitative recovery of CD4+ T-cells (World Health Organization [WHO], 2021).